ABOUT US The Medicinal Organic Chemistry Group is a research group at the Research Institute for Medicines (iMed) focused on the development of new scaffolds to target diseases such as cancer, malaria and tuberculosis. MedOrgChemGroup
We are pleased to announce the recent publication in ChemMedChem!! This study expands the potential of the small molecule RVJB59 as a targeted therapy for breast cancers carrying the clinically relevant R280K and R273H mutants p53. Combining biophysical, mass spectrometry, and computational approaches, we demonstrate that RVJB59 stabilizes mutant p53 and covalently binds to Cys141, highlighting a promising strategy to target cancer with these relevant mutations.
We are pleased to announce the recent publication in EJNMMI Radiopharmacy and Chemistry!! This work reports the development and preclinical evaluation of novel vinyl sulfone-based probes targeting tumor-associated cathepsins for PET imaging. The study was part of Oliviero Cini’s PhD research, which he recently successfully defended.
The Medicinal Organic Chemistry (MOC) Group is delighted to celebrate an important milestone as Oliviero Cini successfully defended his PhD thesis, co-supervised by Professor Maria M. M. Santos. Over the course of his PhD journey, Oliviero has demonstrated outstanding dedication, scientific curiosity, and perseverance. His research has made valuable contributions to our group's scientific endeavors, and his commitment to advancing medicinal chemistry has been truly inspiring.
